(Q33563230)

English

Topical and systemic immunoreaction triggered by intravesical chemotherapy in an N-butyl-N-(4-hydroxybutyl) nitorosamine induced bladder cancer mouse model

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

28 July 2017

Topical and systemic immunoreaction triggered by intravesical chemotherapy in an N-butyl-N-(4-hydroxybutyl) nitorosamine induced bladder cancer mouse model (English)

1 reference

Europe PubMed Central

28 July 2017

author name string

Shunta Hori

1

1 reference

Europe PubMed Central

28 July 2017

Makito Miyake

2

1 reference

Europe PubMed Central

28 July 2017

Yoshihiro Tatsumi

3

1 reference

Europe PubMed Central

28 July 2017

Sayuri Onishi

4

1 reference

Europe PubMed Central

28 July 2017

Yosuke Morizawa

5

1 reference

Europe PubMed Central

28 July 2017

Yasushi Nakai

6

1 reference

Europe PubMed Central

28 July 2017

Nobumichi Tanaka

7

1 reference

Europe PubMed Central

28 July 2017

Kiyohide Fujimoto

8

1 reference

Europe PubMed Central

28 July 2017

language of work or name

0 references

publication date

13 April 2017

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

12

1 reference

Europe PubMed Central

28 July 2017

e0175494

1 reference

Europe PubMed Central

28 July 2017

4

1 reference

Europe PubMed Central

28 July 2017

copyright license

Creative Commons Attribution 4.0 International

13 April 2017

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Bladder cancer cells re-educate TAMs through lactate shuttling in the microfluidic cancer microenvironment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391151

21 June 2018

Using chemo-drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391151

21 June 2018

Sequential intravesical mitomycin plus Bacillus Calmette-Guérin for non-muscle-invasive urothelial bladder carcinoma: translational and phase I clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391151

21 June 2018

Preoperative lymphocyte-to-monocyte ratio predicts clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: a retrospective analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391151

21 June 2018

Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391151

21 June 2018

Prognostic role of NLR in urinary cancers: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391151

21 June 2018

Cancer statistics, 2014

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391151

21 June 2018

Immunotherapy for urothelial carcinoma: current status and perspectives

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391151

21 June 2018

Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391151

21 June 2018

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391151

21 June 2018

Inhibition of IL-17A in tumor microenvironment augments cytotoxicity of tumor-infiltrating lymphocytes in tumor-bearing mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391151

21 June 2018

Enhanced antitumor effect of combination intravesical mitomycin C and bacillus Calmette-Guerin therapy in an orthotopic bladder cancer model.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391151

21 June 2018

Bladder Cancer Immunotherapy: BCG and Beyond.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391151

21 June 2018

Clinical significance of heme oxygenase-1 expression in non-muscle-invasive bladder cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391151

21 June 2018

Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391151

21 June 2018

Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391151

21 June 2018

The optimal management of T1 high-grade bladder cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391151

21 June 2018

Endogenous IL-17 contributes to reduced tumor growth and metastasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391151

21 June 2018

Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391151

21 June 2018

Myeloid-derived suppressor cells as regulators of the immune system

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391151

21 June 2018

Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391151

21 June 2018

History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391151

21 June 2018

Neutrophils and TRAIL: insights into BCG immunotherapy for bladder cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391151

21 June 2018

Current strategies for first and second line intravesical therapy for nonmuscle invasive bladder cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391151

21 June 2018

Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391151

21 June 2018

Calreticulin exposure dictates the immunogenicity of cancer cell death

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391151

21 June 2018

Regulatory T cells in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391151

21 June 2018

IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391151

21 June 2018

Interleukin-17 enhances bFGF-, HGF- and VEGF-induced growth of vascular endothelial cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391151

21 June 2018

Interleukin-17 family members and inflammation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391151

21 June 2018

Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391151

21 June 2018

Role of urothelial cells in BCG immunotherapy for superficial bladder cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391151

21 June 2018

Immunoregulatory T cells in tumor immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391151

21 June 2018

Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391151

21 June 2018

Inoculation of human interleukin-17 gene-transfected Meth-A fibrosarcoma cells induces T cell-dependent tumor-specific immunity in mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391151

21 June 2018

Internalization of bacille Calmette-Guerin by bladder tumor cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5391151

21 June 2018

Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0175494

21 January 2018

Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0175494

21 January 2018

Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guérin-induced antitumor activity.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0175494

21 January 2018

Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0175494

21 January 2018

Accumulation of regulatory T cells in sentinel lymph nodes is a prognostic predictor in patients with node-negative breast cancer.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0175494

21 January 2018

Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0175494

21 January 2018

Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0175494

21 January 2018

Urinary IL‐2 assay for monitoring intravesical bacillus Calmette‐Guérin response of superficial bladder cancer during induction course and maintenance therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/28406993

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/28406993

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/28406993

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall

1 reference

https://pubmed.ncbi.nlm.nih.gov/28406993

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Suppressive effects of cyclophosphamide and gemcitabine on regulatory T-cell induction in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/28406993

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravesical bacillus Calmette-Guérin outcomes in patients with bladder cancer and asymptomatic bacteriuria

1 reference

https://pubmed.ncbi.nlm.nih.gov/28406993

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/28406993

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0175494

1 reference

Europe PubMed Central

28 July 2017

2017PLoSO..1275494H

0 references

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33563230&oldid=1847352545"